The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disorder without an effective therapy to date. In a double-blind, randomized, placebo-controlled trial, 107 patients were prospectively evaluated for efficacy of a novel compound, pirfenidone. The difference in the change in the lowest oxygen saturation by pulse oximetry (SpO2) during a 6-minute exercise test, the primary endpoint, from baseline to 6 months was not significant between the two groups (p = 0.0722). In a prespecified subset of patients who maintained a SpO2 greater than 80% during a 6-minute exercise test at baseline, the lowest SpO2 improved during a 6-minute exercise test in the pirfenidone group at 6 and 9 months (p = 0.0069 and 0.0305, respectively). Positive treatment effect was demonstrated in secondary endpoints: (1) change in VC measurements at 9 months (p = 0.0366) and (2) episodes of acute exacerbation of IPF occurring exclusively in the placebo group during the 9 months (p = 0.0031). Significant adverse events were associated with pirfenidone; however, adherence to treatment regimen was similar between pirfenidone and placebo groups. In conclusion, treatment with pirfenidone improved VC and prevented acute exacerbation of IPF during the 9 months of follow-up. Future long-term studies are needed to clarify the overall safety and efficacy of pirfenidone in IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652 · cited 1×
“In a recent study, there appeared to be significant episodes of acute respiratory decompensations preceding death in patients with progressive IPF (6).”
BackgroundSelf-citationIdiopathic Pulmonary Fibrosis: Relationship between Histopathologic Features and Mortality
KING, T. E., SCHWARZ, M. I., BROWN, K., TOOZE, J. A., COLBY, T. V., WALDRON, J. A., FLINT, A., THURLBECK, W., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.6.2001056 · Cited by 628
Fibrotic Idiopathic Interstitial Pneumonia: The Prognostic Value of Longitudinal Functional Trends
Latsi, P. I., du Bois, R. M., Nicholson, A. G., Colby, T. V., Bisirtzoglou, D., Nikolakopoulou, A., Veeraraghavan, S., Hansell, D. M., & Wells, A. U. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200210-1245oc · Cited by 583
Prognostic Value of Desaturation during a 6-Minute Walk Test in Idiopathic Interstitial Pneumonia
Lama, V. N., Flaherty, K. R., Toews, G. B., Colby, T. V., Travis, W. D., Long, Q., Murray, S., Kazerooni, E. A., Gross, B. H., Lynch, J. P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200302-219oc · Cited by 555
Prognostic Implications of Physiologic and Radiographic Changes in Idiopathic Interstitial Pneumonia
Flaherty, K. R., Mumford, J. A., Murray, S., Kazerooni, E. A., Gross, B. H., Colby, T. V., Travis, W. D., Flint, A., Toews, G. B., Lynch, J. P., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200209-1112oc · Cited by 513
RAGHU, G., CRAIG JOHNSON, W., LOCKHART, D., & MAGETO, Y. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.4.9805017 · Cited by 468
Acute Exacerbation in Idiopathic Pulmonary Fibrosis
Kondoh, Y., Taniguchi, H., Kawabata, Y., Yokoi, T., Suzuki, K., & Takagi, K. (1993) · Chest · doi:10.1378/chest.103.6.1808 · Cited by 457
The clinical diagnosis of pulmonary emphysema; an experimental study.
Fletcher, C. M. (1952) · PubMed · Cited by 433
Raghu, G., Mageto, Y. N., Lockhart, D., Schmidt, R. A., Wood, D. E., & Godwin, J. D. (1999) · Chest · doi:10.1378/chest.116.5.1168 · Cited by 400
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · PubMed · Cited by 358
Assessment of Health-Related Quality of Life in Patients With Interstitial Lung Disease
Chang, J. A., Curtis, J. R., Patrick, D. L., & Raghu, G. (1999) · Chest · doi:10.1378/chest.116.5.1175 · Cited by 302
Akira, M., Hamada, H., Sakatani, M., Kobayashi, C., Nishioka, M., & Yamamoto, S. (1997) · American Journal of Roentgenology · doi:10.2214/ajr.168.1.8976924 · Cited by 298
TAKAHASHI, H., FUJISHIMA, T., KOBA, H., MURAKAMI, S., KUROKAWA, K., SHIBUYA, Y., SHIRATORI, M., KUROKI, Y., & ABE, S. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9910080 · Cited by 291
Self-citationUsual interstitial pneumonia: histologic correlation with high-resolution CT.
Nishimura, K., Kitaichi, M., Izumi, T., Nagai, S., Kanaoka, M., & Itoh, H. (1992) · Radiology · doi:10.1148/radiology.182.2.1732946 · Cited by 267
Self-citationWatters, L. C., Schwarz, M. I., Cherniack, R. M., Waldron, J. A., Dunn, T. L., Stanford, R. E., & King, T. E. (1987) · PubMed · doi:10.1164/arrd.1987.135.3.696 · Cited by 248
Reliability and validity of the chronic respiratory questionnaire (CRQ).
Wijkstra, P. J., TenVergert, E. M., Van Altena, R., Otten, V, Postma, D. S., Kraan, J., & Koeter, G. H. (1994) · Thorax · doi:10.1136/thx.49.5.465 · Cited by 219
Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.
Iyer, S. N., Wild, J. S., Schiedt, M. J., Hyde, D. M., Margolin, S. B., & Giri, S. N. (1995) · PubMed · Cited by 217
Circulating KL-6 Predicts the Outcome of Rapidly Progressive Idiopathic Pulmonary Fibrosis
YOKOYAMA, A., KOHNO, N., HAMADA, H., SAKATANI, M., UEDA, E., KONDO, K., HIRASAWA, Y., & HIWADA, K. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.5.9803115 · Cited by 211
Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome
Gahl, W. A., Brantly, M., Troendle, J., Avila, N. A., Padua, A., Montalvo, C., Cardona, H., Anton Calis, K., & Gochuico, B. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00044-6 · Cited by 203
Comparison of Hallway and Treadmill Six-minute Walk Tests
STEVENS, D., ELPERN, E., SHARMA, K., SZIDON, P., ANKIN, M., & KESTEN, S. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.5.9808139 · Cited by 191
The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis
Hallstrand, T. S., Boitano, L. J., Johnson, W. C., Spada, C. A., Hayes, J. G., & Raghu, G. (2005) · European Respiratory Journal · doi:10.1183/09031936.04.00137203 · Cited by 188
Nakazato, H., Oku, H., Yamane, S., Tsuruta, Y., & Suzuki, R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01758-2 · Cited by 187
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35110-9 · Cited by 181
Gurujeyalakshmi, G., Hollinger, M. A., & Giri, S. N. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.276.2.l311 · Cited by 179
Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38125-x · Cited by 179
Oku, H., Nakazato, H., Horikawa, T., Tsuruta, Y., & Suzuki, R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01757-0 · Cited by 159
Pharmacological Therapy for Idiopathic Pulmonary Fibrosis: Past, Present, and Future
Mason, R. J., Schwarz, M. I., Hunninghake, G. W., & Musson, R. A. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.5.9903009 · Cited by 139
Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals
Misra, H. P., & Rabideau, C. L. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007023532508 · Cited by 135
Nagai, S., HAMADA, K., Shigematsu, M., TANIYAMA, M., Yamauchi, S., & Izumi, T. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.1118 · Cited by 134
Self-citationPirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice
Kehrer, J. P., & Margolin, S. B. (1997) · Toxicology Letters · doi:10.1016/s0378-4274(96)03845-3 · Cited by 81
The Elusive Goal of Therapy for Usual Interstitial Pneumonia
Teirstein, A. S. (2004) · New England Journal of Medicine · doi:10.1056/nejme038182 · Cited by 17
Case 40-2002: A 56-Year-Old Man with Rapidly Worsening Dyspnea
Gong, M. N., & Mark, E. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmcpc020028 · Cited by 10
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Metadata
- Authors
- Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., Sato, A., & Kudoh, S.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-05-01
- Volume
- 171
- Issue
- 9
- Pages
- 1040-1047
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2142941142
- Cited by
- 954
- References
- 36
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.